Company news

Myriad Genetics, Inc. news in 2024

Myriad Genetics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

December 18, 2024

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

December 9, 2024

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

December 9, 2024

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

December 9, 2024

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

December 8, 2024

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

December 8, 2024

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

November 19, 2024

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

November 18, 2024

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

November 12, 2024

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

November 6, 2024

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

November 3, 2024

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

October 29, 2024

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

October 15, 2024

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

October 14, 2024

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

October 7, 2024

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

October 2, 2024

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

September 30, 2024

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

September 17, 2024

Myriad Genetics to Host Investor Event on October 9, 2024

September 4, 2024

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

August 20, 2024

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

August 5, 2024

Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific

July 31, 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

July 30, 2024

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

July 29, 2024

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

July 16, 2024

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

July 10, 2024

Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

July 8, 2024

Myriad Genetics Earns 2024 Great Place To Work® Certification™

July 1, 2024

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

June 10, 2024

Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen

June 3, 2024

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

June 2, 2024

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

May 29, 2024

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

May 22, 2024

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

May 15, 2024

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

May 6, 2024

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

May 6, 2024

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

April 29, 2024

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

April 16, 2024

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

April 15, 2024

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

April 8, 2024

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

March 20, 2024

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

March 19, 2024

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in t...

February 26, 2024

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

February 26, 2024

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

February 20, 2024

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

February 14, 2024

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

January 31, 2024

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

January 29, 2024

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

January 17, 2024

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

January 8, 2024

Older news releases →

Calls in 2024

Decks in 2024